Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3
GEAP202617026APending Publication Date: 2026-10-26MERCK SHARP & DOHME LLC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- GEAP202617026P0
- Authority / Receiving Office
- GE · GE
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-14
- Filing Date
- 2024-12-12
- Publication Date
- 2026-10-26
Abstract
Abstract Azaindazole derivatives useful as inhibitors of NOD-like receptor 3 protein The invention relates to novel compounds of formula (I) and pharmaceutically acceptable salts thereof, which are NLRP3 inhibitors and which can be used for the treatment, prevention, management, alleviation, control or suppression of NLRP3 mediated diseases. The compounds of the present invention can be used for the treatment, prevention or management of NLRP3 mediated diseases, disorders and conditions such as, but not limited to, obesity, nicrisis, pseudonicrisis, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies (DLB) and traumatic brain injury. (I)
Need to check novelty before this filing date? Find Prior Art
